
AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
To own Radware, you have to believe in its position as a specialist in application, network, and now AI security, with enough differentiation to justify a relatively rich earnings multiple and modest revenue growth forecasts. Near term, the big swing factors still look like execution against Q2 guidance, continued traction in cloud and DDoS deals, and how effectively the company uses its US$80 million buyback authorization. The new Dataiku partnership fits into this by pulling Radware’s AI guardian technology into the AI governance conversation earlier, potentially widening its reach within large enterprises, but the immediate financial impact is uncertain and likely limited in the short run. It does, however, slightly rebalance the story toward AI production security as a newer catalyst, alongside existing concerns about valuation, insider selling, and low return on equity.
However, one risk in particular stands out as easy to underestimate. Radware's shares are on the way up, but they could be overextended by 32%. Uncover the fair value now.Explore 4 other fair value estimates on Radware - why the stock might be worth less than half the current price!
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com